Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other 1Genitourinary 1

Conditions

Prostatic Neoplasms 51Urinary Bladder Neoplasms 15Breast Neoplasms 10Carcinoma, Renal Cell 8Colorectal Neoplasms 7Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 4Motor Activity 3Colonic Neoplasms 3Urologic Neoplasms 2Urologic Diseases 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Prostate Cancer Metastatic 2Neoplasms by Site 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Kidney Failure, Chronic 2Esophageal Neoplasms 2COVID-19 2Breast Neoplasms, Male 2

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Massage 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pulmonary Disease, Chronic Obstructive × Standard of Care × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡